COX-2 inhibitors and cardiovascular risk
- 1 January 2006
- journal article
- research article
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 96 (10) , 401-406
- https://doi.org/10.1160/th06-07-0385
Abstract
Schattauer GmbH - Verlag für Medizin und Naturwissenschaften ist ein renommierter Herausgeber von Fachbüchern, -zeitschriften und -software. Besuchen Sie unser Internetangebot mit Onlinezugang zu unseren ZeitschriftenartikelnKeywords
This publication has 13 references indexed in Scilit:
- Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunitiesJournal of Clinical Investigation, 2005
- Roles of thromboxane A2 and prostacyclin in the development of atherosclerosis in apoE-deficient miceJournal of Clinical Investigation, 2004
- Celecoxib, a Cyclooxygenase-2 Inhibitor, Reduces Neointimal Hyperplasia Through Inhibition of Akt SignalingCirculation, 2004
- Relationship Between Selective Cyclooxygenase-2 Inhibitors and Acute Myocardial Infarction in Older AdultsCirculation, 2004
- Cyclooxygenases: new forms, new inhibitors, and lessons from the clinicThe FASEB Journal, 2004
- Constitutive Expression and Involvement of Cyclooxygenase-2 in Human MegakaryocytopoiesisArteriosclerosis, Thrombosis, and Vascular Biology, 2004
- Cyclooxygenase COX-2a, a novel COX-2 mRNA variant, in platelets from patients after coronary artery bypass graftingThrombosis and Haemostasis, 2004
- Differential Effects of Selective Cyclooxygenase-2 Inhibitors on Endothelial Function in Salt-Induced HypertensionCirculation, 2003
- COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expressionProceedings of the National Academy of Sciences, 2002
- Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed plateletsProceedings of the National Academy of Sciences, 2002